The global market for long oligo pool synthesis for capture is poised for significant growth, according to a recent report added to ResearchAndMarkets.com’s offerings. This market is expected to expand from $1.73 billion in 2025 to $1.97 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.7%.
The increasing adoption of next-generation sequencing technologies, coupled with a rising demand for targeted sequencing solutions, is fueling this growth. Investments in cancer genomics research, the use of gene panel testing, and advancements in array-based synthesis technologies are further driving the demand for scalable and accurate capture solutions in both research and clinical settings.
Looking ahead, the market is projected to reach $3.31 billion by 2030, with a CAGR of 13.9% from 2026. This growth is attributed to the rising demand for precision oncology, the integration of artificial intelligence into probe design, increased investments in synthetic biology, and the expansion of clinical genomic diagnostics. There is also a growing need for scalable multiplexed enrichment methods, which support complex genomic analyses.
Several key trends are shaping the long oligo pool synthesis market. These include the adoption of high-plex target enrichment panels, the demand for custom capture probe libraries, the use of automated probe design platforms, and expanding applications of CRISPR screening. Additionally, there is a focus on cost-effective, high-throughput oligonucleotide synthesis to enhance workflow efficiency.
Precision medicine is a major driver of market growth. The expanding use of genomic sequencing is enabling personalized approaches to disease diagnosis, treatment selection, biomarker identification, and patient stratification. Long oligo pool synthesis plays a crucial role in these applications by providing accurate genomic enrichment and customized probe design for targeted sequencing in clinical and research environments.
Industry data indicates a growing adoption of personalized treatments. The Personalized Medicine Coalition reports that the U.S. Food and Drug Administration approved 16 new personalized treatments in 2023, up from six in 2022. Of these, seven were oncology drugs, while others targeted various diseases and medical conditions. This trend underscores the increasing role of genomics in developing targeted therapies and is expected to boost demand for advanced capture technologies.
Strategic partnerships are also contributing to market growth. For example, in January 2023, Twist Bioscience Corporation collaborated with Centogene N.V. to launch three next-generation sequencing target enrichment panels for rare disease and hereditary cancer research and diagnostics. These panels were curated using CENTOGENE’s extensive Biodatabank and synthesized by Twist Bioscience to support precise variant detection.
The prevalence and identification of genetic disorders are further driving the market. Improvements in genetic screening and diagnostics enable healthcare professionals to detect more disease-associated mutations and genetic variants. Capture-based oligo synthesis facilitates precise targeting and enrichment of specific genomic regions, supporting accurate diagnosis, personalized treatment strategies, and targeted therapeutic development.
In the United Kingdom, the number of individuals living with cystic fibrosis increased from 11,148 in 2022 to 11,318 in 2023, according to the Cystic Fibrosis Trust. As genetic testing becomes more integrated into healthcare systems, the demand for reliable targeted sequencing and enrichment technologies is expected to rise.
Geographically, North America was the largest region in the long oligo pool synthesis for capture market in 2025, with Asia-Pacific projected to be the fastest-growing region during the forecast period. The report covers regions including Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, and countries such as Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
The report segments the market by product type, synthesis method, application, and end-users. It also provides data on market size, growth, and competitive market share, covering a forecast period from 2026 to 2030.
Footnotes:
- The market for long oligo pool synthesis is projected to grow from $1.73 billion in 2025 to $1.97 billion in 2026. Source.
- The market is expected to reach $3.31 billion by 2030, expanding at a CAGR of 13.9% from 2026. Source.
- Twist Bioscience partnered with Centogene N.V. to launch sequencing panels for rare disease and hereditary cancer research. Source.
Featured Image: Megapixl @ Scyther5
